Accessibility Menu
Proteonomix logo

Proteonomix(OTC) PROT

Market Cap$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-100%
1 Year+7,900%
1 Month+7,900%
$0.00
+0%
+0.00Today
Proteonomix last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-14
Proteonomix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7,900%USD 0.002026-03-23
1 month+7,900%USD 0.002026-03-23
3 month+7,900%USD 0.002025-12-29
Year to date+7,900%USD 0.002025-12-29
1 year+7,900%USD 0.002024-12-27
3 year+7,900%USD 0.002023-04-27
5 year-99.55%USD 0.022021-05-13
Since inception-100%USD 3.502006-10-03

Proteonomix Financials at a Glance

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.32K

Net Income (TTM)

-$1.56M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

14.93 (High)

Price

$0.00

Volume

250

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 1, 2024

PROT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Proteonomix

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics utilizing human cells and their derivatives. The company offers innovative products aimed at addressing various health conditions, including skin aging and liver disease.

Products and Services
  • Proteoderm: An anti-aging skin cream that reduces wrinkles
  • UMK-121: A treatment for liver disease using approved drugs to mobilize stem cells
  • StromaCel: A cardiac treatment using stem cells to repair heart tissue
Growth Outlook
  • Recent advancements in stem cell therapies show significant market potential
  • Increasing demand for anti-aging products supports growth in the skincare sector
  • Strategic partnerships may enhance product development and market reach
Financial Highlights
  • Recent quarterly revenue of $2,290 indicates potential for growth
  • Net income for Q2 2012 was $1,444,000, showcasing operational efficiency
  • Cash and cash equivalents stood at $2,398,357, providing liquidity for operations
Proteonomix, Inc. operates in the dynamic biotechnology sector, focusing on innovative solutions for health challenges. The company's diverse product offerings, including Proteoderm, UMK-121, and StromaCel, position it well within the growing markets of skincare and regenerative medicine. Recent financial data indicates a positive trajectory, with a notable net income in the latest quarter and a solid cash position. The growth outlook remains promising, driven by increasing demand for advanced therapeutics and potential strategic partnerships. Investors may find Proteonomix an intriguing opportunity in the biotechnology landscape.
AI Generated • Jul 1, 2026

Industry

Biotechnology

Headquarters

Hawthorne, NJ 07506, US

PROT Financials

Key Financial Metrics (TTM)

Gross Margin

101.97%

Operating Margin

-5026.15%

Net Income Margin

-5322.26%

Return on Equity

38.77%

Return on Capital

N/A

Return on Assets

-41.42%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.81M

Volume

250

Avg. Volume

4.032

Financials (TTM)

Gross Profit

$23.40K

Operating Income

-$3.75M

EBITDA

-$1.12M

Operating Cash Flow

-$1.27M

Capital Expenditure

-$77.97K

Free Cash Flow

-$1.35M

Cash & ST Invst.

$2.40M

Total Debt

$3.22M

Proteonomix Performance Analysis

Proteonomix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32011-09-30N/A
Q42011-12-31-0.1%
Q12012-03-31-67.3%
Q22012-06-30-100.0%
Proteonomix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32011-09-30-37.6%
Q42011-12-314.8%
Q12012-03-31-390.4%
Q22012-06-30164.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2012YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.98

N/A

Employees

164

N/A

Net Income

$1.44M

+627.0%

EBITDA

$1.54M

+1170.8%

Quarterly Fundamentals

Name
Q2 2012YOY CHG

Total Cash

$2.40M

+466506.4%

Total Debt

$3.22M

-13.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$3.22M

-13.5%

Return on Assets

-41.42%

N/A

Return on Invested Capital

35.35%

N/A

Free Cash Flow

-$595.08K

-1204.3%

Operating Cash Flow

-$560.59K

-1128.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CALACalithera Biosciences, Inc.
$0.00+0.00%
OMMHOmnimmune Holdings, Inc.
$0.00-0.00%
VSMDVasamed, Inc.
$0.00+0.00%
BIIOBionovate Technologies Corp
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About PROT

What is the current price of Proteonomix?

Proteonomix is trading at $0.00 per share.

What is the 52-week range for Proteonomix?

Over the past 52 weeks, Proteonomix has traded between $0.00 and $0.00.

How much debt does Proteonomix have?

Proteonomix total debt is unavailable.

How much cash does Proteonomix have on hand?

Proteonomix does not have cash on hand data available.

What is Proteonomix’s dividend yield?

Proteonomix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.